CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

2026.02.06
With continuous technological iteration in CAR-T cell therapy, fourth-generation CAR-T is increasingly demonstrating substantial clinical potential. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The meeting brought together leading hematology experts from China and abroad, focusing on cutting-edge advances and national health strategy priorities, fostering in-depth academic exchange and exploration of new directions in the field.
Annual Review Professor Bing Xu: Interpreting New Paradigms and Future Pathways in the Diagnosis and Treatment of Follicular Lymphoma

Annual Review Professor Bing Xu: Interpreting New Paradigms and Future Pathways in the Diagnosis and Treatment of Follicular Lymphoma

2026.02.06
From January 16 to 18, 2026, the Working Meeting of the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Myeloma Expert Committee and the 2026 CSCO Academic Conference on Hematologic Malignancies were held in Haikou, China. During the meeting, Professor Bing Xu of the First Affiliated Hospital of Xiamen University systematically outlined a comprehensive new framework for follicular lymphoma (FL), spanning precision risk stratification, therapeutic decision-making, and future research directions. His presentation provided valuable guidance for clinicians seeking to optimize treatment strategies and anticipate future developments in the field.
CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

2026.02.06
Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome that poses significant clinical challenges due to marked patient heterogeneity, a high proportion of relapsed or refractory cases, and limited options for precision-based interventions. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The conference brought together leading hematology experts from China and abroad, focusing on cutting-edge scientific advances and national health strategy priorities, fostering in-depth academic exchange and exploration of future directions in the field.
CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

2026.02.06
The “Tianjin Model” of hematopoietic stem cell transplantation (HSCT) is a distinctive transplant system that integrates standardization, precision, and innovation. It has been progressively developed through nearly four decades of continuous exploration and generational knowledge transfer at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (also known as the Tianjin Institute of Hematology).
Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

2026.02.06
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) was recently successfully held in Orlando, United States. As the year’s flagship event in hematology, the meeting presented a concentrated series of groundbreaking advances in lymphoma research, offering new directions for the optimization of clinical practice.
Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

2026.02.05
At the beginning of 2026, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was grandly held in Beijing. The meeting focused on frontier advances and standardized practices in urologic oncology and brought together numerous domestic experts and scholars in the field.
Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

2026.02.05
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on cutting-edge topics in the diagnosis and treatment of urologic malignancies, aiming to establish a high-level academic exchange platform and to promote innovation in clinical thinking and standardized practice among young physicians.
Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

2026.02.04
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on the latest frontiers in urologic oncology and brought together many leading mid-career and young experts from across China, aiming to elevate clinical practice through intellectual exchange.
ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

2026.02.04
In the global field of hepatocellular carcinoma (HCC) treatment, the synergistic use of targeted therapy and immunotherapy has led to breakthrough progress, significantly prolonging survival for patients with advanced disease and bringing renewed hope to countless individuals. Yet medical progress never stands still. How to further transcend existing treatment paradigms and unlock deeper survival benefits remains a persistent goal for clinicians worldwide.
ESMO International Perspective | Professor Maria Reig: Large International Multicenter Evidence Supports the Inclusion of EBRT in the BCLC Staging and Treatment Algorithm

ESMO International Perspective | Professor Maria Reig: Large International Multicenter Evidence Supports the Inclusion of EBRT in the BCLC Staging and Treatment Algorithm

2026.02.04
The Barcelona Clinic Liver Cancer (BCLC) staging system is the cornerstone framework guiding treatment decisions for hepatocellular carcinoma (HCC). Its fundamental role lies in stratifying patients according to three key prognostic determinants—tumor burden, liver function, and performance status—thereby aligning prognosis assessment with evidence-based treatment recommendations for each disease stage.